Physical Address

304 North Cardinal St.
Dorchester Center, MA 02124

D-Health Trial Hints at Cardiovascular Benefits of Vitamin-D Caps

In a large prospective randomized trial, an analysis revealed that adults aged 60 or older who took high monthly doses of vitamin D for 5 years did not exhibit a significant decrease in the overall risk of cardiovascular (CV) events. However, there may have been some benefits related to other CV outcomes. The group that received vitamin D showed lower rates of myocardial infarction (HR = 0.81; 95% CI, 0.67-0.98) and coronary revascularization (HR = 0.89; 95% CI, 0.78-1.01). Nevertheless, JoAnn E. Manson, MD, DrPH, MACP, FAHA, cautioned that these results are likely chance findings. This study garnered significant attention in the field of cardiology last week. D-Health Trial Hints at Cardiovascular Benefits of Vitamin-D Caps

Atrial fibrillation is the most common arrhythmia, with an increased risk associated with age and a higher likelihood of stroke, heart failure, and mortality. Vitamin D has been shown to influence the shape and electrical activity of the heart’s atria, suggesting a potential preventive role in atrial fibrillation. Calcitriol, an active form of vitamin D, possesses various essential biological functions, including reducing inflammation, inhibiting the proliferation of vascular smooth muscle, and regulating the renin-angiotensin-aldosterone system. D-Health Trial Hints at Cardiovascular Benefits of Vitamin-D Caps

Large D-Health Trial Suggests Potential Cardiovascular Benefits of Vitamin-D Caps

The risk reductions observed in the mixed primary- and secondary-prevention population with vitamin D were modest in absolute terms but reached a significant 19% reduction in the case of myocardial infarction (MI). However, this finding contradicted the results of the Women’s Health Initiative Trial, which included women participants and utilized a lower dose of vitamin D. Nevertheless, vitamin D supplementation was associated with potential benefits in reducing the risk of MI and a decrease of 11% in the risk of coronary revascularization.

D-Health Trial Hints at Cardiovascular Benefits of Vitamin-D Caps

In a trial involving over 20,000 older adults, vitamin D supplementation exhibited a trend towards reducing the risk of major cardiovascular events compared to a placebo, which differs from previous studies. The Finnish Vitamin D Trial (FIND), conducted at the University of Eastern Finland from 2012 to 2018, aimed to evaluate whether monthly vitamin D supplementation improves the health outcomes of older adults. Additionally, a subgroup analysis hinted at a potentially reduced CV event risk from vitamin D supplementation among individuals who entered the trial on statins or other cardiovascular medications.

Findings from Extensive D-Health Trial Point to Cardiovascular Benefits of Vitamin-D Caps

Researchers reported that the death of the recipient of the world’s first genetically modified pig heart transplant in 2022 was likely caused by a combination of complex factors, including the presence of a latent porcine virus. The primary objective of the study was to investigate the relationship between vitamin D supplementation and the prevalence of cardiovascular diseases and malignancies. The five-year study involved 2,495 participants, including men aged 60 or older and women aged 65 or older.

While a previous analysis using the D-Health cohort did not find a reduction in mortality due to cardiovascular disease or all-cause mortality with vitamin D supplementation, its impact on the incidence of major cardiovascular events was not determined. Researchers also reported that eicosapentaenoic acid, the active ingredient in certain omega-3 fatty acids, demonstrated anti-inflammatory, cytoprotective, and lipid changes in endothelial cells exposed to air pollution.

Promising Cardiovascular Effects of Vitamin-D Caps Emerge from Extensive D-Health Trial

The participants in the study were divided into three groups: a placebo group and two groups receiving vitamin D3 supplementation, with one group receiving a daily supplement of 40 micrograms (1600 IU) and the other group receiving 80 micrograms (3200 IU) per day.

Leave a Reply

Your email address will not be published. Required fields are marked *